E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Obstructive Pulmonary Disease |
Chronisch obstructieve longziekten |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10010952 |
E.1.2 | Term | COPD |
E.1.2 | System Organ Class | 100000004855 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1.1) to study whether and to what extent oral administration of morphine SR improves health-related quality of life among patients with advanced COPD;
1.2) to explore whether and to what extent oral administration of morphine SR leads to adverse respiratory effects in patients with advanced COPD.
|
|
E.2.2 | Secondary objectives of the trial |
2.1) to study whether and to what extent oral administration of morphine SR improves exercise capacity among patients with advanced COPD;
2.2) to study the relationship between severity and description of breathlessness and response to morphine SR among patients with advanced COPD;
2.3) to analyse the cost-effectives of oral administration of morphine SR in patients with advanced COPD.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• diagnosis of COPD according to the current Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (GOLD) ;
• optimal pharmacological treatment;
• Grade 3 or 4 dyspnea on the mMRC;
• optimal non-pharmacological treatment defined as completed a comprehensive pulmonary rehabilitation program.
|
|
E.4 | Principal exclusion criteria |
• history of substance misuse;
• exacerbation of COPD within two weeks of study enrolment;
• waiting list for lung transplantation;
• pregnant or childbearing potential not using contraception;
• renal failure (creatinine clearance <15mL/min);
• age under 18;
• not being able to read or fill in the questionnaires
or diary;
• allergy for morphine or its excipients;
• concomitant use of irreversible MAO blockers;
• use of opioids. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Change in disease-specific health-related quality of life (COPD Assessment Test (CAT);
• Change in respiratory parameters: arterial blood gas (partial pressure of carbon dioxide (pCO2); partial pressure of oxygen (pO2); respiratory rate; pulse oximetric saturation (SpO2); transcutaneous carbon dioxide (PtcCO2); Overnight oximetry; lung function.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline, 1, 2 and 4 weeks |
|
E.5.2 | Secondary end point(s) |
• Change in exercise capacity (6 minute walking distance test);
• Change in functional capacity (care dependency (Care Dependency Scale) and mobility (Timed ‘Up & Go’ test).
• sensory and affective dimensions of dyspnea (Multidimensional Dyspnea Profile);
• impact of dyspnea (modified Pulmonary Functional Status and Dyspnea Questionnaire);
• dyspnea (Numeric Rating Scale)
• adverse affects (including nausea, vomiting, constipation, and drowsiness)
• compliance;
• exacerbations (defined as an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medication).
• Costs and cost-effectiveness
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Baseline, 1, 2 and 4 weeks |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS.
Criteria for termination of the study prematurely:
• Statistically significant higher proportion of deceased patients in the intervention group;
• Statistically significant higher proportion of hospitalized patients in the intervention group.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |